The Medicare-X Choice Act of 2026 creates a new public health plan called the Medicare Exchange health plan, which would be available to individuals and small groups starting in 2028. The bill establishes two dedicated funds to finance the plan's creation and technology updates, appropriating $1 billion each for fiscal year 2027. Under the plan, the government would set premiums to cover full costs, and reimbursement rates for doctors and hospitals would generally match current Medicare rates, with potential increases for rural areas. The legislation also requires health care providers who participate in traditional Medicare to also accept patients in this new plan, while prohibiting insurers from placing additional restrictions on enrollees. Additionally, the bill expands tax credits for people buying insurance, fixes the "family glitch" that currently limits subsidy eligibility for some workers, and authorizes the government to negotiate prices for prescription drugs.
The Secure Drug Supply Chain Act of 2026 aims to protect the U.S. pharmaceutical supply by preventing the importation of counterfeit or unsafe drugs from countries like China and others designated as adversarial. It requires drug manufacturers to report quarterly details about the origins of their active ingredients and key starting materials, specifically highlighting those sourced from China or other foreign countries of concern. The bill also strengthens enforcement by allowing the government to ban imports from facilities using forced labor or violating sanctions, and it mandates the destruction of refused drugs that pose significant public health risks. Additionally, the law establishes new reporting requirements to track supply chain vulnerabilities and directs the Health and Human Services Secretary to issue regulations and guidance to implement these measures.
This bill creates a new program to speed up the approval process for specific over-the-counter drugs that could offer significant public health benefits. Drug companies can request this "priority" status for new medications intended for conditions that currently require a prescription, provided the drugs are new or contain active ingredients never seen in nonprescription products. If approved, the FDA will assign senior staff and specialized teams to work closely with the companies, offering faster guidance and more efficient review schedules while maintaining the same safety and effectiveness standards. The program includes a requirement to publish a list of eligible health conditions and will expire in September 2032 unless renewed by Congress.
The Water Emergency and Technical Assistance Act of 2026 establishes a funding mechanism to help states and water treatment facilities respond to emergencies that pose a significant danger to public health, such as sewer overflows or cybersecurity incidents. Under this bill, the Environmental Protection Agency Administrator can provide grants and technical assistance for activities that prevent or mitigate health risks but would be too costly for ratepayers to fund on their own. The legislation authorizes $50 million annually from fiscal years 2027 through 2031 to support these emergency efforts and also increases the existing funding for drinking water emergencies during the same period.
This resolution commemorates the 250th anniversary of the United States in 2026 while reaffirming the importance of prevention and access to healthcare. It expresses the sense of Congress that a healthy nation is essential for preserving the ideals of life, liberty, and the pursuit of happiness for future generations. The bill encourages efforts to improve preventive care, screenings, health education, and access to clean air and water. It does not create new laws or funding but serves as a symbolic statement to renew national commitment to public health.
